Nicox and pSivida to Collaborate to Develop a Sustained Release Drug to Lower IOP

October 12, 2017: By Jon Swedien

NicoxNicox and pSivida have agreed to potentially combine Nicox’s nitric oxide (NO)-donating compounds with pSivida’s bioerodible sustained-release drug delivery system to develop an IOP-lowering treatment for glaucoma and ocular hypertension, the companies announced Oct. 10.

Nicox and pSivida will collaborate on the selection of NO-donating product candidates from Nicox’s research portfolio to combine with pSivida’s technology. pSivida will be responsible for initial development activities and receive undisclosed payments from Nicox, the companies said.

pSividaThe firms may elect to conduct more detailed nonclinical studies to generate preclinical data and evaluate additional compounds. Nicox would make additional payments for any incremental development activities for each product candidate selected by Nicox to advance, the companies said.

New intellectual property from the collaboration will be jointly owned, the companies said. Nicox and pSivida will negotiate a separate license agreement for any product candidate they plan to commercialize under the collaboration, they said.

Expected payments from Nicox associated with this agreement are not considered material to Nicox’s financial statements at this time, the company said.

Nicox is an international ophthalmic company based in Paris. pSivida, headquartered in Watertown, Massachusetts, is focused on sustained-release drug products for treating eye diseases.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

Refocus Completes PMA Application for VisAbility as Treatment for Presbyopia

Novaliq’s NovaTears+Omega-3 Approved in Europe for Dry Eye

CooperVision Acquires Paragon Vision Sciences for $80 Million

AYOXXA Biosystems Launches Test for Biomarkers in Retinal Disease

Glaukos Announces New Patent for Glaucoma Stent Implanted in Schlemm’s Canal

Fortress Biotech Forms Tamid Bio Subsidiary; Lead Candidate is Ophthalmic Gene Therapy for MPS I

Samsung Launches App that Adjusts QLED TV Settings for Color-blind Viewers

Solar Eclipse Burns Crescent Wound in Woman’s Unprotected Retina

US Judge Refuses to Dismiss Allergan Suit against Imprimis

BioLight Sells IOPtima to Chengdu Kanghong Pharmaceutical Group for $56 Million

Regeneron Ending Eylea, Nesvacumab Combo Program

UK Retinal Drugmaker Exonate Forms Clinical Advisory Board

US FDA Approves RxSight’s Light Adjustable Lens and Light Delivery Device

EMA to Move to Amsterdam due to Brexit

First Subject Dosed in Nevakar’s Phase III Trial of NVK-002 for Myopia in Children

ProQR Doses First Patient in Phase I/II Trial for Leber’s Congenital Amaurosis 10

Aston EyeTech Raises $6.6 Million in Series A Equity Round

Ellex Raises $17.7 Million in Private Placement

Genentech’s Lampalizumab Fails Second Phase III Study in Geographic Atrophy

Judge Declares Mistrial in Corruption Trial of Melgen, Menendez

Coming soon

2017 Dry Eye Products Report: A Global Market Analysis for 2016 to 2022